Champions Oncology (CSBR) Cash from Financing Activities (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Cash from Financing Activities of -$19000.0 for Q2 2026, up 40.62% year-over-year from -$13511.1 in Q2 2025, and up 47.22% quarter-over-quarter from -$36000.0 in Q1 2026.
Champions Oncology (CSBR) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Champions Oncology's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$19000.0 for Q2 2026.
- In Q2 2026, Cash from Financing Activities rose 40.62% year-over-year to -$19000.0; the TTM figure through Apr 2026 stood at $99000.0 (down 41.76% YoY), while the FY2026 annual figure was $99000.0, down 41.76% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at -$19000.0, up from -$36000.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $239000.0 in Q4 2024, with the low at -$590000.0 in Q3 2023.
- The 5-year median for Cash from Financing Activities is -$19000.0 (2026), against an average of -$10866.7.
- The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities surged 221.43% in 2022, then tumbled 568.75% in 2023.
- Champions Oncology's Cash from Financing Activities stood at $86000.0 in 2022, then surged by 55.81% to $134000.0 in 2023, then jumped by 78.36% to $239000.0 in 2024, then retreated by 29.71% to $168000.0 in 2025, then tumbled by 111.31% to -$19000.0 in 2026.
- Business Quant data shows CSBR's Cash from Financing Activities at -$19000.0 in Q2 2026, -$36000.0 in Q1 2026, and $168000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Champions Oncology | 68.61 Mn | 68.61 Mn | 7.03 Mn | -19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -19,000.00 |
| Apr 30, 2026 | -19,000.00 |
| Jan 31, 2026 | -36,000.00 |
| Jan 31, 2026 | -36,000.00 |
| Oct 31, 2025 | 168,000.00 |
| Oct 31, 2025 | 168,000.00 |
| Jul 31, 2025 | -14,000.00 |
| Jul 31, 2025 | -14,000.00 |
| Apr 30, 2025 | -32,000.00 |
| Apr 30, 2025 | -32,000.00 |
| Oct 31, 2024 | 239,000.00 |
| Oct 31, 2024 | 239,000.00 |
| Jul 31, 2024 | -37,000.00 |
| Jul 31, 2024 | -37,000.00 |
| Apr 30, 2024 | -37,000.00 |
| Apr 30, 2024 | -37,000.00 |
| Jan 31, 2024 | -34,000.00 |
| Jan 31, 2024 | -34,000.00 |
| Oct 31, 2023 | 134,000.00 |
| Oct 31, 2023 | 134,000.00 |